{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"13","value":"217.0"},{"groupId":"OG001","spread":"34","value":"209.9"},{"groupId":"OG002","spread":"18","value":"247.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Avelumab Cycle 1/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31","value":"53.39"},{"groupId":"OG001","spread":"25","value":"63.12"},{"groupId":"OG002","spread":"28","value":"47.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Avelumab Cycle 1/Day8-168 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26","value":"233.8"},{"groupId":"OG001","spread":"20","value":"277.4"},{"groupId":"OG002","spread":"33","value":"263.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Avelumab Cycle 1/Day15-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15","value":"253.7"},{"groupId":"OG001","spread":"30","value":"295.2"},{"groupId":"OG002","spread":"20","value":"254.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Avelumab Cycle 2/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24","value":"242.0"},{"groupId":"OG001","spread":"29","value":"331.1"},{"groupId":"OG002","spread":"44","value":"304.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Avelumab Cycle 4/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17","value":"248.2"},{"groupId":"OG001","spread":"17","value":"292.4"},{"comment":"Geometric Coefficient of Variation was not estimable as there was only 1 participant analyzed.","groupId":"OG002","spread":"NA","value":"270.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Avelumab Cycle 6/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation was not estimable as there was only 1 participant analyzed.","groupId":"OG001","spread":"NA","value":"318.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Avelumab Cycle 10/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22","value":"17570"},{"groupId":"OG001","spread":"55","value":"34420"},{"groupId":"OG002","spread":"44","value":"38200"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"PD 0360324 Cycle 1/Day1-30 Minutes (Min)/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"109","value":"1324"},{"groupId":"OG001","spread":"43","value":"8846"},{"groupId":"OG002","spread":"47","value":"6598"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"PD 0360324 Cycle 1/Day8-168 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27","value":"16620"},{"groupId":"OG001","spread":"29","value":"32550"},{"groupId":"OG002","spread":"51","value":"46130"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"PD 0360324 Cycle 1/Day15-30 min/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20","value":"17050"},{"groupId":"OG001","spread":"1072","value":"11690"},{"groupId":"OG002","spread":"16","value":"57420"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"PD 0360324 Cycle 2/Day1-30 min/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2","value":"17700"},{"groupId":"OG001","spread":"8","value":"27060"},{"groupId":"OG002","spread":"51","value":"43650"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"PD 0360324 Cycle 4/Day1-30 min/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12","value":"15590"},{"groupId":"OG001","spread":"8","value":"35140"},{"groupId":"OG002","spread":"27","value":"58620"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"PD 0360324 Cycle 6/Day1-30 min/EOI"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation was not estimable as there was only 1 participant analyzed.","groupId":"OG001","spread":"NA","value":"33100"},{"groupId":"OG002","spread":"11668","value":"3216"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"PD 0360324 Cycle 10/Day1-30 min/EOI"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Cmax is maximum observed plasma concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"During Phase 1b participants received PD 0360324 50 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG000","title":"Combination C Phase 1b: PD 0360324 50 mg + Avelumab"},{"description":"During Phase 1b participants received PD 0360324 100 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG001","title":"Combination C Phase 1b: PD 0360324 100 mg + Avelumab"},{"description":"During Phase 1b participants received PD 0360324 150 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG002","title":"Combination C Phase 1b: PD 0360324 150 mg + Avelumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set included all participants who had received at least one dose of study drug and who had at least one of the PK concentrations of interest for Avelumab, Utomilumab, PD 0360324, PF-04518600. Here, \"Number of participants analyzed'' signifies number of participants evaluable for this outcome measure, where \"Number Analyzed\" signifies number of participants evaluable for specified time points.","reportingStatus":"POSTED","timeFrame":"1 hour (i.e. at the end of infusion) post-dose on Day 1,15 of Cycle 1; Day 8 of Cycle 1 (non-dosing); Day 1 of Cycle 2, 4, 6 and Cycle 10","title":"Maximum Observed Plasma Concentration (Cmax) of Avelumab and PD 0360324 in Combination C","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter"}